Streetbeat News

Earnings

SANM

Sanmina Corporation (NASDAQ: SANM) reported Q1 adjusted EPS of $1.30, surpassing the consensus estimate of $1.22, and sales of $1.88B, slightly above the $1.87B estimate. However, these figures represent a decrease from the previous year, with earnings down 20.73% and sales down 20.58% from the same period last year.

Portfolio Pulse from totan@benzinga.com

January 29, 2024 | 9:03 pm

DAIO

Data I/O Corporation reported preliminary Q4 net sales of $6.8 million and bookings of $7.2 million.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 9:03 pm

WWD

Woodward Inc. reported Q1 2024 adjusted earnings per share (EPS) of $1.45, surpassing the analyst estimate of $1.10. Sales for the quarter were $787 million, also exceeding the expected $748.29 million.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 9:02 pm

TRNS

Transcat (NASDAQ:TRNS) reported Q3 adjusted EPS of $0.56, surpassing the $0.35 estimate, a 60% year-over-year increase. Sales reached $65.17M, exceeding the $63.68M estimate and marking a 13.53% increase from the previous year.

Portfolio Pulse from totan@benzinga.com

January 29, 2024 | 9:02 pm

CRWD

CrowdStrike Holdings (NASDAQ:CRWD) has been analyzed by 39 analysts, showing a range of opinions. The average 12-month price target is $248.26, up 14.47% from the previous target. Analysts from firms like JMP Securities, Keybanc, and Morgan Stanley have raised their price targets, reflecting a positive outlook on the company's performance. CrowdStrike's financials show strong revenue growth and net margin, but a lower ROE compared to industry averages. The company's low debt-to-equity ratio indicates a healthy balance of financing.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 9:01 pm

Zoom Video Comms Inc. (NASDAQ:ZM) has seen a slight drop in its stock price in the current session and has experienced declines over the past month and year. Investors are examining the company's P/E ratio, which is lower than the Software industry average, suggesting that the stock might be undervalued or that shareholders have low growth expectations.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 7:30 pm

AMD

MCHP

QCOM

QRVO

SLAB

SWKS

The semiconductor industry is experiencing mixed Q4 earnings results, with KeyBanc Capital Markets providing insights and ratings for six companies reporting in the upcoming week: AMD, MCHP, QRVO, QCOM, SLAB, and SWKS. Texas Instruments and Intel reported lower-than-expected results and guidance, while optimism remains for AMD, and solid results are expected for smartphone semiconductor companies. The IoT sector, represented by SLAB, is anticipated to show gradual recovery.

Portfolio Pulse from Surbhi Jain

January 29, 2024 | 7:27 pm

BFRG

CDLX

PBLA

SNCE

SOFI

U.S. stocks saw a slight increase, with the Nasdaq Composite up by 75 points. The Dow and S&P 500 also experienced modest gains. Consumer discretionary shares led the gains, while energy shares declined following a 1.3% drop in crude oil prices. Science 37 Holdings (SNCE) surged 16% after agreeing to be acquired by eMed. SoFi Technologies (SOFI) jumped 16% on strong quarterly revenue, and Cardlytics (CDLX) rose 28% after a settlement agreement and updated Q4 results. Conversely, Panbela Therapeutics (PBLA) plummeted 67% due to a public offering, Bullfrog AI Holdings (BFRG) fell 24% after a shelf offering, and Bloom Energy (BE) dropped 7% after a downgrade by B of A Securities. The Federal Reserve Bank of Dallas reported a decline in Texas manufacturing activity.

Portfolio Pulse from Avi Kapoor

January 29, 2024 | 7:24 pm

Raymond James analyst Olivia Tong upgraded Colgate-Palmolive Co (NYSE:CL) to Outperform from Market Perform with a $91 price target, citing strong Q4 FY23 earnings and positive 2024 outlook. The company reported a 7% YOY sales growth, beating estimates, and expects 1%-4% net sales growth for FY24. Risks in Latin America are noted, but offset by strengths in Mexico and Brazil. Wells Fargo, UBS, and Morgan Stanley analysts also raised their price targets for CL, reflecting a positive sentiment among analysts.

Portfolio Pulse from Lekha Gupta

January 29, 2024 | 7:08 pm

HARP

MRK

Merck & Co Inc (MRK) is experiencing a stock rally ahead of its Q4 earnings report, driven by optimism around its cancer drug Keytruda, which has received four FDA approvals since November 2023. The latest approval on Jan. 12 allows Keytruda to be used with chemoradiotherapy for certain cervical cancers. Merck's stock has also been positively influenced by the acquisition of Harpoon Therapeutics Inc (HARP) for $680 million, aimed at enhancing its cancer treatment pipeline. A technical indicator, the Golden Cross, has occurred for Merck stock, suggesting continued upward momentum.

Portfolio Pulse from Surbhi Jain

January 29, 2024 | 7:05 pm